anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The discrepancy in sleep timing between weekdays and weekends - social jetlag (SJL) - is known to negatively affect student quality of life (QOL). However, the association between social jetlag and physical/mental QOL among adolescents and the precise effect of social jetlag on depressive symptoms and daytime sleepiness remains unknown. This study investigated the longitudinal course, risk factors, and effects of social jetlag, a circadian misalignment, in a school-based cohort. The participants were 427 students (13.3 ± 0.6 years, 45.2% girls) from five junior high schools. We performed a baseline survey in 2019 and a 1-year follow-up survey in 2020. Depressive symptoms, QOL, and daytime sleepiness were assessed using the Birleson Depression Self-Rating Scale for Children, Paediatric Quality of Life Inventory, and Paediatric Daytime Sleepiness Scale. In the baseline survey, 49.6% of the students reported SJL ≥1 h, and 17.1% reported SJL ≥2 h. Among them, 37.2% and 6.8% reported persistent SJL at follow-up, respectively. New incidences of SJL ≥1 h were associated with older age, non-attainment of menarche or voice changes, and longer duration of smartphone use, whereas its persistence was associated with a later chronotype. Persistence of SJL ≥1 h and ≥2 h predicted depressive symptoms and daytime sleepiness at follow-up, whereas new incidences of SJL ≥2 h predicted lower QOL. In conclusion, social jetlag has a persistent course, and daytime functioning can deteriorate as social jetlag becomes chronic. Our findings suggest the need for intensive interventions for social jetlag among adolescents.
PURPOSE: To provide a method for improving a therapeutic efficacy of fat- soluble corticosteroid and suppressing a side effect by introducing the corticosteroid into a nonionic amphiphilic lipid phase and forming vesicles comprising lamellas when being dispersed in an aqueous phase. CONSTITUTION: This method for improving a therapeutic efficacy of a fat-soluble corticosteroid comprises a use of a nonionic lipid of the formula [(n) is an average statistic value of 2-6; R is R1 , R2 CO (R1 is a linear or branched 12-18C aliphatic group; R2 is a linear or branched 11-17C aliphatic group); R' is R1 ] as an amphiphilic lipid when forming vesicles by introducing a corticosteroid (e.g. 21-acetic acid-17-pyopionic acid-hydrocortisone) into an amphiphilic lipid phase capable of forming vesicles comprising lamellas when dispersed in water. A phosphoric ester of a fatty alcohol (e.g. dicetyl phosphate) is preferably used in combination. The using amount of the corticosteroid and also the side effect can be reduced because the therapeutic efficacy of the corticosteroid is improved.
Genicular nerve phenol nerve ablation All procedures will be performed by a fellowship trained interventional pain physician in a fluoroscopy suite in Hotel Dieu Hospital using sterile precautions. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. IV access and saline lock obtained per our usual clinic protocol. Patients will be positioned supine on the procedure table. The affected knee will be prepped and draped using standard sterile technique and 1-2cc of 1% lidocaine will be administered to the area for local anesthetic. Phenol nerve ablation will be performed via ultrasound guidance.
ARC1779 Injection will be investigated in 4 cohorts of TTP patients as an uncontrolled, open-label study. Patients with vWD-2b will be enrolled in an additional cohort in a randomized, blinded, double-dummy, and placebo-controlled study.

Collectively, patients representing 3 different vWF-related platelet function disorders: TTP in remission, acute TTP, and vWD-2b will be treated in a total of 5 cohorts. Three cohorts will consist of patients who are status post an episode of TTP ("TTP Remission Cohorts") and will be treated with ARC1779 Injection in a dose- and duration-escalation design. In parallel, a single cohort of patients with acute TTP ("Acute TTP Cohort") will be treated according to an individual patient titration-to-response paradigm. This cohort will be opened for enrollment at the beginning of the study and closed after all of the other cohorts are completed. Also in parallel, a single cohort of patients with vWD-2b ("vWD-2b Cohort") will begin enrollment at the commencement of the study and continue independently of the course of the TTP Remission Cohorts. Up to 4 patients will be included in each of the TTP cohorts. The vWD-2b Cohort is expected to consist of up to 12 vWD-2b patients.
This study used a 2-cohort, nonrandomized, open-label, multicenter design. Cohort 1: The first cohort was to be comprised of approximately 200 patients with RMS, who were newly prescribed commercially available fingolimod 0.5 mg/day. Cohort 2: The second cohort was to be comprised of approximately 200 RMS patients who had been on commercially available fingolimod 0.5 mg/day continuously without interruption of treatment for at least ≥ 2 years. Patients from both cohorts were recruited simultaneously from up to 125 MS centers in the United States. Both cohorts ran concurrently. The study consisted of 2 periods: Screening (up to 4 weeks) and Treatment period from Baseline (end of screening period considered as Day 1) up to 12 months with visits conducted at 3,6 and 12 months with a 14 day follow-up post treatment..
318,269. Johnson, J. Y., (I. G. Farbenindustrie Akt.-Ges.). April 2, 1928. Vitamins.-Antirachitic preparations are obtained by treating ergosterol or substances containing it with corona discharges obtained by using continuous currents of high voltage or alternating currents of high voltage and frequency, or with electric corpuscular rays such as rapidlymoving electrons or ions or with R÷ntgen rays, while excluding oxygen, halogens, and the like. 'The ergosterol may be used in the solid, diluted, or vapour-like state. In the examples, (1) ergosterol is passed in suspension in a neutral gas such as nitrogen (or, if dissolved, in fog-like form) through an apparatus of the Cotterell-Moeller kind having spark electrodes and using a current at several hundred kilovolts; the progress of the treatment may be controlled by observing the ultraviolet absorption spectrum, and reduced pressure may be employed; (2) a solution of ergosterol in heptaine or the like is treated in an ozonizer using a high frequency alternating current having more than 1000 alternations per second and a tension of more than 1 kilovolt, a current of inert gas being passed through the solution; (3) ergosterol is subjected to the action of electrons or ions which are accelerated by an electrostatic field; the material may be spread in a thin layer on a dish and treated in a cathode tube, or, when using cathode rays of very high velocity, it may be effected outside the tube, the rays passing through an aluminium window; canal rays may also be used with an indifferent gas at low pressure; (4) ergosterol is treated in solid form with X-rays, a substance such as barium platinocyanide or zinc sulphide being added if desired to effect a secondary emission of ultraviolet rays. The electric treatment above described may be combined with a treatment with ultraviolet rays. Specifications 292,926; and 293,255, [Class 1 (i), Chemical processes &c.], are referred to.
A method of perlecan isolation (from the EHS tumor) which produces “clean” (i.e. substantially “pure”) perlecan is disclosed. Clean perlecan is thus produced in sufficient quantities for use in a number of different in vitro and in vivo assays. In addition, this isolation method exploits a newly discovered aggregating property of a  ˜ 220 kDa heparan sulfate proteoglycan (HSPG) observed during gel filtration chromatography, which allows it to be effectively separated from non-aggregating perlecan. The method employs specific cation exchange, anion exchange, molecular sieve chromatography and immobilized GAG affinity chromatography. It is demonstrated that there are no other contaminating proteins in the perlecan and HSPG preparations, and that the perlecan core protein is intact. Improved, clean perlecan based, rodent models of fibrillar amyloid protein deposition, accumulation and/or persistence in tissues are disclosed.
Bacterial preparations for medical use are obtained by freezing a suspension of bacteria, drying the mass in a vacuum without thawing it, and disintegrating the dried mass by subjecting it, in the presence of hard grinding bodies to a smooth oscillating motion over continuously curved paths, such as is produced by means of the pulverizing apparatus described in Specifications 439,968, [Group II], and 475,888, [Group XIII].  The disintegrated bacteria may be extracted with water, salt solution or other solvent to obtain solutions which may be used directly or may be dried at low temperature, or the disintegrated bacteria may be used in making salves or emulsions.  According to an example calf dysentery bacilli cultivated on an agar-agar medium covered with a foil of cellulose hydrate are rinsed off the medium with water and the suspension obtained is placed in a ball mill, frozen, and dried in a high vacuum.  The mill is then shaken on an oscillating sieve until the bacteria are completely disintegrated. Physiological salt solution is introduced and the mill again shaken.  The extract obtained is centrifuged and a preservative such as the sodium salt of 2-ethyl-mercury-mercaptobenzoxazole-5-carboxylic acid is added. Other examples relate to the treatment of typhoid bacilli and gonococci in a similar manner.
The delayed treatment group will receive the same intervention as the immediate treatment group, but 24 weeks after randomization. The intervention includes using an online guided self-help programme Spring that is based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps. The user of the programme also receives up to 3 hours of guidance by a trained therapist.
In Massachusetts (MA), partner notification is routinely offered for new HIV and infectious syphilis cases, but there are no formal partner notification services for gonorrhea and chlamydia. Electronic partner notification (ePN), which allows patients to anonymously notify their partners of sexually transmitted infection exposure, could fill this gap. We evaluated the acceptability of and ideal characteristics for a statewide ePN service in MA. We performed semistructured interviews with patients at a Boston area sexual health clinic and conducted focus groups with clinicians and Massachusetts Department of Public Health Field Epidemiologists (FEs). We developed a codebook and thematically analyzed interview and focus group data; 25% of interviews were double coded. We identified six main themes from our data: (1) partner notification is a relational process and (2) partner notification is situation dependent. There are three pairs of challenges and core values for an effective ePN system: (3) stigmatization versus inclusivity, (4) trust versus mistrust, and (5) privacy versus helpful information sharing. Therefore, (6) a statewide ePN platform must be customizable at each possible step. Although ePN was acceptable across all three groups, the likelihood of individual use was grounded in a patient's sociocultural context, interpersonal relationships, trust in the platform and health authorities, desire to avoid stigmatization, and privacy needs. These factors are best accommodated by a platform that adapts to users' preferences and needs. ePN presents an opportunity to link partners at risk for gonorrhea or chlamydia to clinical care that is complementary to the more labor-intensive FE role.
Prodn. of total bacterial extracts for vaccine prodn. is effected by (a) rendering bacteria virulent in vivo, (b) culturing the bacteria in vitro, (c) concentrating the bacterial cells by ultrafiltration in a closed system, and (d) subjecting the cells to ultrasonic lysis under controlled conditions. Pref. step (a) is effected by injecting the bacteria into the pleural cavity of a rabbit and recovering the pleural exudate after 20 hr. Step (c) is effected using a membrane with a molecular wt. cutoff of 100,000. Step (d) is effected in a continuous-flow chamber with Ti probes supplied at 1000 W and emitting at 22 kHz.
FIELD: medicine, immunology. SUBSTANCE: invention relates to methods of preparing curative preparations from immunized donor blood, in part, to methods of preparing human antidiphtheritic imuunoglobulin for intravenous administration. In 30 days after immunization with diphtheritic anatoxin blood is taken off in donors. Blood plasma with titer value of antidiphtheritic antibodies 1:160 and above is taken off and boiler mixture containing antidiphtheritic antibodies 1: 1280, not less, is formed. Then blood plasma is fractionated by alcohol method at low temperatures. The end product is obtained as solution of human antidiphtheritic immunoglobulin. Obtained preparation is homologous one, it shows high specificity and effectiveness in treatment of patients with diphtheria, especially in treatment of patients with enhanced sensitivity to heterologous protein and does not cause allergic complications. EFFECT: improved method of preparing, valuable properties. 1 tbl, 1 ex
Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 10 weeks.
The invention discloses a medicine composition for treating toothache. The composition is prepared from, by weight, 8-10 parts of radix ophiopogonis, 6-10 parts of dried orange peel, 5-8 parts of red peony root, 5-8 parts of dahurian patrinia herb, 5-8 parts of rhizoma anemarrhenae, 4-6 parts of rhizoma cimicifugae, 4-6 parts of radix angelicae dahuricae, 4-6 parts of radix scutellariae, 4-6 parts of typhae pollen and 5-8 parts of liquorice root. Radix ophiopogonis in the formula is used for nourishing yin and moistening the lung, clearing away heart-fire and relieving restlessness, tonifying stomach and promoting secretion of saliva or body fluid, dried orange peel is used for regulating qi and tonifying the stomach, clearing away heat and eliminating phlegm, and radix ophiopogonis and dried orange peel serve as monarch drugs together. Red peony root, dahurian patrinia herb and rhizoma anemarrhenae are used for purging fire for removing toxin and swelling and serve as ministerial drugs. Rhizoma cimicifugae, radix angelicae dahuricae and radix scutellariae are used for eliminating stagnated fire, typhae pollen is used for promoting circulation of blood and qi and stopping pain, and rhizoma cimicifugae, radix angelicae dahuricae, radix scutellariae and typhae pollen serve as adjuvant drugs together. Liquorice root can coordinate the drug actions, relieve spasm and alleviate pain, and serves as a messenger drug. The drugs are compatible and together have the effects of clearing away the stomach purging fire, removing toxin, eliminating swelling, eliminating stagnated heat and stopping toothache.
Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
PURPOSE:To obtain a poultice having good workability, excellent feeling to the skin and high tackiness and useful as an anti-inflammatory and analgesic agent for bone fracture, bruise, sprain, etc., by crosslinking an acrylic compound with a polyvalent metal compound and using the obtained crosslinked acrylic compound as a gel plaster component. CONSTITUTION:An acrylic compound is made to react with a water-soluble polyvalent metal compound (e.g. aluminum chloride) and a hardly soluble polyvalent metal compound (e.g. aluminum hydroxide) to obtain a crosslinked acrylic compound. The produced compound is mixed with a drug active component to obtain a gel plaster, which is applied to a substrate to form the objective poultice. The acrylic compound is a copolymer of acrylic acid and an acrylic acid salt, a mixture of said copolymer and polyacrylic acid or a mixture of a polyacrylic acid and a polyacrylic acid salt. The amount of the polyvalent metal compound is 0.01-1.0 equivalent based on the acrylic compound and the weight ratio of the water-soluble compound to the hardly soluble compound is 9/1-3/7.
The present invention belongs to the field of molecular immunology, discloses six antigen epitope molecule simulating peptides capable of exciting human body's tubercle bacillus antagonizing protective immunoreaction, and provides recombinant tubercle bacillus antigen polyepitope peptides, which are fusion peptides with the amino acid sequences as shown in SEQ ID No.1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 separately. The present invention also provides their construction process and use. These polyepitope peptides, cell and animal experiments show, can excite efficient specific tubercle bacillus antagonizing protective immune response. The present invention may be used in preventing and treating tuberculosis.
Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
The present invention provides a hemostatic material which is excellent in hemostatic property, biodegradability and bioabsorbability, uniformity and stability of the quality, as well as reduces a risk of contamination with a pathogenic organism derived from an animal. The hemostatic material comprises a thrombin and a synthetic polypeptide capable of forming a triple helical structure. The polypeptide may show a peak of the molecular weight in the range from 5×10 4  to 100×10 4  in the molecular weight distribution. The polypeptide may contain at least a peptide unit represented by the formula: -Pro-X-Gly- (in the formula, X represents Pro or Hyp). The thrombin may be a recombinant. In the hemostatic material, the proportion of the thrombin may be about 0.1 to 500 units (U) relative to 1 mg of the polypeptide. The hemostatic material may further comprise a binder component having biodegradability and bioabsorbability. The hemostatic material may be formed on a substrate.
Background: Despite recognition of the importance of genetic factors in the pathogenesis of MND and the increasing availability of genetic testing, testing practice remains highly variable. With the arrival of gene-targeted therapies there is a growing need to promptly identify actionable genetic results and patient death before receipt of results raises ethical dilemmas and limits access to novel therapies. Objective: To identify pathogenic mutations within a London tertiary MND center and their correlation with family history. To record waiting times for genetic results and deaths prior to receipt of results. Methods: In this series of 100 cases, genetic testing was offered to all patients with an MND diagnosis from the tertiary clinic. Data on demographics, disease progression and a detailed family history were taken. Time to receipt of genetic results and patient deaths prior to this were recorded.  Results: Of the 97 patients who accepted testing a genetic cause was identified in 10%, including seven C9orf72 and two positive SOD1 cases. Only three patients with positive genetic findings had a family history of MND, although alternative neurological diagnoses and symptoms in the family were frequently reported. 14% of patients who underwent testing were deceased by the time results were received, including one actionable SOD1 case.  Conclusions: Genetic testing should be made available to all patients who receive an MND diagnosis as family history alone is inadequate to identify potential familial cases. Time to receipt of results remains a significant issue due to the limited life expectancy following diagnosis.
Risk Summary

Published literature reports that ciprofloxacin is present in human milk following intravenous and oral administration. There is no information regarding effects of ciprofloxacin on milk production or the breastfed infant. Because of the potential risk of serious adverse reactions in breastfed infants, including arthropathy shown in juvenile animal studies [see Use in Specific Populations (8.4), (Clinical Considerations)], for most indications a lactating woman may consider pumping and discarding breast milk during treatment with ciprofloxacin and an additional two days (five half-lives) after the last dose. Alternatively, advise a woman that breastfeeding is not recommended during treatment with ciprofloxacin and for an additional two days (five half-lives) after the last dose. 

However, for inhalation anthrax (post exposure), during an incident resulting in exposure to anthrax, the risk-benefit assessment of continuing breastfeeding while the mother (and potentially the infant) is (are) on ciprofloxacin may be acceptable [see Dosage and Administration (2.2), Pediatric Use (8.4), and Clinical Studies (14.2)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ciprofloxacin and any potential adverse effects on the breastfed child from ciprofloxacin or from the underlying maternal condition. 

Clinical Considerations

Ciprofloxacin may cause intestinal flora alteration of the breastfeeding infant. Advise a woman to monitor the breastfed infant for loose or bloody stools and candidiasis (thrush, diaper rash).
Certain embodiments of the present invention provide for a system and method for managing clinical documents for claims processing. In an embodiment, the method includes receiving a command to submit an invoice to a payer. The method also includes acquiring a first set of files from an electronic medical records database according to a first set of rules. The first set of rules provide for acquiring a first set of files required for submission to a payer. The method also includes displaying an identifier for the first set of files to a user for approval. The first set of files may be transmitted to the payer. In an embodiment, the method may also include receiving a request for additional information from the payer. A second set of files may be acquired according to a second set of rules. The second set of files may be transmitted to the payer.
The invention provides a drug sustained-release system for treating tumours, which comprises a drug carrier, a drug and a surface active agent. The drug carrier is a biodegradable polymer fibre. The drug is a dichloroacetic acid salt covered and loaded on the drug carrier. The surface active agent is covered and loaded on the drug carrier, wherein the drug accounts for 15-70 wt % of the drug sustained-release system and the surface active agent accounts for 0-15 wt % of the drug sustained-release system. The invention further provides a preparation method of the drug sustained-release system for treating the tumours. The drug sustained-release system can realize the sustained release of the local drug so that the concentration of the local drug around the tumours is in a scope of a therapeutic effect window; however, the drug concentration except the tumours and in body fluid is in a health scope, therefore, the utilization rate of the drugs is increased and the therapeutic effect is guaranteed as well as the usage amount of the drugs is reduced and the toxic side effects caused by large dosage of the drugs are reduced.